Soleno Therapeutics (SLNO) Return on Capital Employed (2014 - 2026)
Soleno Therapeutics (SLNO) reported Return on Capital Employed of 16.37% for Q1 2026, up 8435.0% year-over-year from 0.19% in Q1 2025, and up 805.01% on a QoQ basis from 1.81% in Q4 2025.
Soleno Therapeutics (SLNO) has 13 years of Return on Capital Employed data on file, last reported at 16.37% in Q1 2026.
- Quarterly Return on Capital Employed rose 8435.0% year-over-year to 16.37% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 16.37% (up 8435.0% YoY) and the FY2025 annual result came in at 2.44%, up 8160.0% from the prior year.
- Return on Capital Employed improved to 16.37% in Q1 2026 per SLNO's latest filing, from 1.81% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 16.37% in Q1 2026 and bottomed at 181.25% in Q3 2023.
- The 5-year median for Return on Capital Employed is 63.6% (2024), against an average of 72.94%.
- The widest annual swing landed in 2023, when Return on Capital Employed sank 10255 bps; it then jumped 14405 bps in 2024.
- Tracing SLNO's Return on Capital Employed over 5 years: stood at 111.27% in 2022, then soared by 66 bps to 37.41% in 2023, then slumped by 70 bps to 63.6% in 2024, then jumped by 103 bps to 1.81% in 2025, then surged by 805 bps to 16.37% in 2026.
- Per Business Quant, the three latest SLNO Return on Capital Employed figures stand at 16.37% (Q1 2026), 1.81% (Q4 2025), and 20.63% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | 16.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.37% |
| Dec 31, 2025 | 1.81% |
| Sep 30, 2025 | -20.63% |
| Jun 30, 2025 | -62.97% |
| Mar 31, 2025 | -67.99% |
| Dec 31, 2024 | -63.60% |
| Sep 30, 2024 | -49.91% |
| Jun 30, 2024 | -31.95% |
| Mar 31, 2024 | -34.96% |
| Dec 31, 2023 | -37.41% |
| Sep 30, 2023 | -181.25% |
| Jun 30, 2023 | -176.00% |
| Mar 31, 2023 | -177.60% |
| Dec 31, 2022 | -111.27% |
| Sep 30, 2022 | -80.46% |
| Jun 30, 2022 | -73.45% |
| Mar 31, 2022 | -88.68% |
| Dec 31, 2021 | -101.53% |
| Sep 30, 2021 | -99.60% |
| Jun 30, 2021 | -81.24% |
| Mar 31, 2021 | -70.45% |
| Dec 31, 2020 | -60.72% |
| Sep 30, 2020 | -52.11% |
| Jun 30, 2020 | -70.79% |
| Mar 31, 2020 | -99.76% |
| Dec 31, 2019 | -82.45% |
| Sep 30, 2019 | -72.45% |
| Jun 30, 2019 | -53.54% |
| Mar 31, 2019 | -40.78% |
| Dec 31, 2018 | -40.73% |
| Sep 30, 2018 | -53.97% |
| Jun 30, 2018 | -44.75% |
| Mar 31, 2018 | -39.94% |
| Dec 31, 2017 | -39.30% |
| Sep 30, 2017 | -33.04% |
| Jun 30, 2017 | -27.14% |
| Mar 31, 2017 | -42.58% |
| Dec 31, 2016 | -198.09% |
| Sep 30, 2016 | -233.87% |
| Jun 30, 2016 | -238.20% |
| Mar 31, 2016 | -225.15% |
| Dec 31, 2015 | -267.14% |
| Sep 30, 2015 | -524.67% |
| Jun 30, 2015 | 219.79% |
| Mar 31, 2015 | -84.45% |
| Dec 31, 2014 | -137.37% |